Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Withdrawn 1Terminated 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 10Neoplasm Metastasis 3Lung Neoplasms 3Adenocarcinoma of Lung 3cMET-dysregulated Advanced Solid Tumors 2Melanoma 2Glioblastoma 2cMET Dysegulation Advanced Solid Tumors 1Sarcoma 1Malignant Non-small Cell Neoplasm of Lung Stage IV 1Liver Neoplasms 1Kidney Neoplasms 1Hepatic Impairment 1Gliosarcoma 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma 1Bronchial Neoplasms 1Advanced Solid Tumor 1

Interventions

Carboplatin 27Paclitaxel 23Cisplatin 22Gemcitabine 17pembrolizumab 15Fluorouracil 9Pemetrexed 8Everolimus 8Docetaxel 8Cetuximab 8Radiotherapy, Intensity-Modulated 7Radiotherapy 7130-nm albumin-bound paclitaxel 7Sorafenib 6Nivolumab 6Bevacizumab 6Axitinib 6epothilone B 5Sunitinib 5Radiation 5Panitumumab 5Cyclophosphamide 5trebananib 4reolysin 4padeliporfin 4lenvatinib 4Irinotecan 4Gefitinib 4vosaroxin 3volociximab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Carcinoma × capmatinib × Clear all
NCT05110196 2026-04-07

Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC.

Novartis

Phase 4 Completed
50 enrolled
Thoracic

Bronchial Neoplasms, Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡